Cited by 963Cancer Immunotherapy and BiomarkersT-cell and B-cell ImmunologyImmune Cell Function and Interaction

The DOI matches its Crossref record; 157 of the 159 references it cites were found in a registry or an index.

TIM3 comes of age as an inhibitory receptor

Open access

Wolf, Yochai, Anderson, Ana C., Kuchroo, Vijay K.·2020·Nature Reviews Immunology

DOI 10.1038/s41577-019-0224-6PMC PMC7327798

Open this paper in CoChat — free account Open PDF

Abstract

T cell immunoglobulin and mucin domain-containing protein 3 (TIM3), a member of the TIM family, was originally identified as a receptor expressed on interferon-γ-producing CD4+ and CD8+ T cells. Initial data indicated that TIM3 functioned as a 'co-inhibitory' or 'checkpoint' receptor, but due to the lack of a definable inhibitory signalling motif, it was also suggested that TIM3 might act as a co-stimulatory receptor. Recent studies have shown that TIM3 is part of a module that contains multiple co-inhibitory receptors (checkpoint receptors), which are co-expressed and co-regulated on dysfunctional or 'exhausted' T cells in chronic viral infections and cancer. Furthermore, co-blockade of TIM3 and programmed cell death 1 (PD1) can result in tumour regression in preclinical models and can improve anticancer T cell responses in patients with advanced cancers. Here, we highlight the developments in understanding TIM3 biology, including novel ligand identification and the discovery of loss-of-function mutations associated with human disease. In addition, we summarize emerging data from human clinical trials showing that TIM3 indeed acts as a 'checkpoint' receptor and that inhibition of TIM3 enhances the antitumour effect of PD1 blockade.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41577-019-0224-6

Cites

157 of 157 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
Nishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Self-citation
Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade
Miller, B. C., Sen, D. R., Al Abosy, R., Bi, K., Virkud, Y. V., LaFleur, M. W., Yates, K. B., Lako, A., Felt, K., Naik, G. S., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0312-6 · Cited by 2,087
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Self-citation
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Im, S. J., Hashimoto, M., Gerner, M. Y., Lee, J., Kissick, H. T., Burger, M. C., Shan, Q., Hale, J. S., Lee, J., Nasti, T. H., et al. (2016) · Nature · doi:10.1038/nature19330 · Cited by 2,070
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
Self-citation
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
Sade-Feldman, M., Yizhak, K., Bjorgaard, S. L., Ray, J. P., de Boer, C. G., Jenkins, R. W., Lieb, D. J., Chen, J. H., Frederick, D. T., Barzily-Rokni, M., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.038 · Cited by 2,053
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868

Show all 159 references

Research works printed but not linked: 2

Weiss, G. J. et al. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in patients (pts) with advanced solid tumors. J. Immunother. Cancer 5, 86 (2017).
Davar, D. et al. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal antibody, in combination with TSR-042 (anti-PD-1) in patients with colorectal cancer and post-PD-1 NSCLC and melanoma. J. Immunother. Cancer 6, 115 (2018).

Sorted by citations

Items 901–963 of 963

Walking the tightrope: Balancing immune checkpoints and their inhibitors in host defence against bacterial infections
PALOUNKOVÁ, A., Frejlachova, A., Kovaříková, A., Chrdle, A., & Langhansová, H. (2026) · Journal of Applied Biomedicine · doi:10.32725/jab.2026.001
Inhibitory receptor agonists: Emerging strategies in immune modulation
Adam, K. R., Suhail, A., Kuchroo, V. K., & Vignali, D. A. A. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20241217
Self-citation
Optimisation d'un vaccin thérapeutique anti-tumoral par association à un traitement anti-angiogénique
Mougel, A. (2021) · theses.fr (ABES) · doi:10.70675/a66d14dezcc33z4350z8827zd97cd6f3328c
Characterization of the Tumor Microenvironment in Chronic Lymphocytic Leukemia by Mass Cytometry : Implications for Immunotherapy
Wierz, M. (2020) · theses.fr (ABES) · doi:10.70675/80454a47z3b6bz4b8bza0c3z684d69f087b3
La Galectine-9 induite par les radiations ionisantes, une nouvelle cible thérapeutique,dans le cancer du sein triple négatif ?
Lerévérend, C. (2023) · theses.fr (ABES) · doi:10.70675/c5b9cabaz796bz48b6z8847z1557e179c148
TIM-3 in Cardiovascular Disease
Yousif, L. I. E., Sijtema, A. G., Chevalier, M. J., de Boer, R. A., & Meijers, W. C. (2026) · Current Heart Failure Reports · doi:10.1007/s11897-026-00755-y
Marqueurs génétiques et moléculaires de l'hétérogénéïté NK : impact sur leurs applications en hématologie
Ferron, E. (2024) · theses.fr (ABES) · doi:10.70675/f7ee5cbez3975z4d1fz908cz5a84a3a5f736
Etude des réponses T CD8+ après transfert de gène par rAAV ciblant le muscle
Jeanpierre, L. (2024) · theses.fr (ABES) · doi:10.70675/430aceacz50d2z426bz907dz876c55d1e935
Evaluation de deux nouvelles stratégies thérapeutiques ciblant les exosomes tumoraux de Carcinomes du Nasopharynx (CNP) : Proposition d'une stratégie d'Immunothérapie ciblant la galectine-9 et d'une Thérapie Photodynamique au 5-ALA
Trioën, C. (2024) · theses.fr (ABES) · doi:10.70675/7c132518z8997z4d01z8084z87c06a661e5a
Immunomodulation des lymphocytes Vγ9Vδ2 dans les leucémies aigües
Floch, A.-C. L. (2023) · theses.fr (ABES) · doi:10.70675/b4e332efz0a66z4c9az85eaz8eea012e9839
HAVCR2 in subcutaneous panniculitis‐like T cell lymphoma: comment on the article by Chambers et al
Chen, A. A. Y., Schwarzkopf, R., Schrader, I., & Chen, L. Y. C. (2026) · Arthritis & Rheumatology · doi:10.1002/art.70174
Radiation-induced MYB reduction unleashes TIM-3 expression in NK cells to attenuate antitumor immunity in colorectal cancer
Tao, G., Guo, X., Xiong, J., Yan, S., Guo, X., Hu, K., Tai, W., Bu, L., Qiu, H., & Wu, Q. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08097-y
β‐Mannosyl Triazoles as Mimics of Galactosyl Galectin‐3 and Galectin‐9 N‐Terminal Domain Inhibitors
Sjövall, F., & Nilsson, U. J. (2026) · ChemBioChem · doi:10.1002/cbic.70319
Role of innate immunity in cancer immunology
Mantravadi, H. B., Kumari, N., Pandey, M., Gopalakrishnan, V., & Mandlik, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-41551-7.00005-9
Peripheral Regulatory T Cells Display Dynamic Memory Subset Frequency and Inhibitory Marker Expression Across Pregnancy
Mulugeta, N., Peters, M. Q., Tobey, C., Wong, J., Spray, A. L. P., Armistead, B., Jiang, Y., Katz, R., Shree, R. S., Vojtech, L. N., et al. (2026) · American Journal of Reproductive Immunology · doi:10.1111/aji.70238
Adipose-derived mesenchymal stromal cells promote an exhaustion-associated phenotype in T cells through TIM-3 upregulation independent of PD-1
Mirshafiei, S., Absalan, F., Yousefi, B., Shariat, M., Talei, A. R., Baharlou, R., Mehdipour, F., & Ghaderi, A. A. (2026) · Discover Oncology · doi:10.1007/s12672-026-05116-8
A Comprehensive Immune Checkpoint Phenotype Predicts Response and Survival to PD ‐1 Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Fiedler, M., Baumann, L., Eichberger, J., Gottsauner, M., Schuderer, J. G., Schulz, D., Meier, J., Bauer, R. J., Poeck, H., Grube, M., et al. (2026) · Head & Neck · doi:10.1002/hed.70313
TNFAIP3 Reprograms T Cell Exhaustion and Restores Anti-Leukemia Immunity in Acute Myeloid Leukemia
Li, Y., Wu, H., Bai, J., Peng, X., Chen, Y., Zhang, J., 张连生, & Li, L. (2026) · Cancer Management and Research · doi:10.2147/cmar.s592664
Chronic and emerging immune-related adverse events from immune checkpoint inhibitors
Frey, C. (2026) · Disease and Therapeutics · doi:10.1016/j.dist.2026.100011
Immunotherapy Landscape of Advanced Clear Cell Renal Cell Carcinoma: Targeting the Cancer-Immunity Cycle and Future Perspectives
Jin, X., Yang, J., Miao, D., Xiong, W., & Xiong, Z. (2026) · Biomedicines · doi:10.3390/biomedicines14061181
Renal Cell Carcinoma: Integrating Histology, Multiomics, and Targeted Therapeutic Strategies
Ongaro, L., Amodeo, A., Crestani, A., Gianfrancesco, L. D., Giannarini, G., Garaffa, G., Simonato, A., Porreca, A., Pavan, N., & Claps, F. (2026) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-032-24071-2_6
Breakthroughs in HBV-related HCC Therapy: The Unmatched Potential of Immune Checkpoint Inhibitors
Liu, C., Chang, L., Yan, Y., Ji, H., Ma, J., Sun, H. S., & Wang, L. (2026) · Current Treatment Options in Oncology · doi:10.1007/s11864-026-01395-z
Spatially-Resolved Multiomic Atlas of Leiomyosarcoma Identifies Two Clinically Relevant Epigenetically-Driven Cell StatesPreprint
Denu, R. A., Zheng, Z., Jiang, Y., Satpati, S., Kochat, V., Anand, K., Truong, D. D., Lynch, A. R., Padron, W. I., Ingram, D. R., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.22.726988
CheckDyn: a multi-cohort computational framework for profiling treatment-induced immune checkpoint dynamics and predicting adaptive resistance to immune checkpoint blockade
Hu, Y., & Xie, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1847297
From monoclonals to bispecific T cell engagers: the evolving antibody-based therapy landscape in acute myeloid leukemia
Rasouli, M., Dalem, M., Raaijmakers, M. H. G. P., Katsikis, P. D., & Erkeland, S. J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1803185
Regulation of antiviral immunity by PD-1 during respiratory syncitial virus infection and upon vaccination
Rodríguez‐Guilarte, L., Méndez, C., Rojas, M. F., Pereira-Sánchez, P., Ríos, M., Muñóz, J. T., Farías, M. A., Bueno, S. M., & Kalergis, A. M. (2026) · iScience · doi:10.1016/j.isci.2026.116157
PD‐1 and TIM‐3 Expression on Peripheral Blood T Cells in HTLV‐1‐Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) and Their Correlations With Disease Stage and Proviral Load
Siyadat, P., Maghsudlu, M., Kheirandish, M., Ajorloo, M., Zemorshidi, F., Sheikhi, M., Vahidi, Z., Boostani, R., & Sharifi, Z. (2026) · Journal of Medical Virology · doi:10.1002/jmv.71003
Assessment of CTLA-4, LAG-3, and TIM-3 Expression in Pediatric Patients With β-Thalassemia Major and Their Association With Alloimmunization
Mansour, M. M., El-Hamid, M. E.-S. A., Dawoud, A. M., Derbaly, S. A. E., Mansour, M. M., & Younis, Y. A. H. S. (2026) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2026.151008
Fusion protein-mediated costimulation in engineered T cells: from intrinsic signaling to tumor microenvironment rewiring
Toumi, R., Guenette, S., & Oda, S. K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1819470
Ablating Satb1 reprograms the differentiation trajectory of exhausted CD8+ T subsets to enhance antitumor immunity
Wu, L., Jiang, H., Gao, J., Ji, X., Chen, Y., Ma, Z., Li, X., Wang, J., Zang, Y., Zhang, J. Y., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1744549
The Evolving Landscape of Immune Regulation and Immunotherapy in Cholangiocarcinoma and Biliary Tract Cancer
Rizk, E. M., Foley, P. A., & Osataphan, S. A. (2026) · Cancers · doi:10.3390/cancers18122001
Lineage-specific and context-dependent dynamics of immune checkpoint receptors define activation-associated programs in human γδ T cellsPreprint
Corsale, A. M., Simone, M. D., Cerapio, J., Presti, E. L., Pizzolato, G., Avellone, C., Dieli, C., Marchiafava, S., Paola, L. D., Dieli, F., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10087888/v1
Inflammatory genital strain of Chlamydia trachomatis elicits a Th17 immune response
Figueroa, A. L., Magill, I., Zemmour, D., & Starnbach, M. N. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag177
Qibai Pingfei Capsule ameliorates NK‑cell dysfunction in COPD: Insights from single‑cell sequencing in a randomized multicenter double‑blinded placebo‑controlled trial
Shi, M., Zhang, L., Tang, S., Wang, Y., Ding, H. B., Wu, D. W., Ma, X., Wang, C., Liu, M., Lü, L., et al. (2026) · Phytomedicine · doi:10.1016/j.phymed.2026.158570
Long-term survivors of melanoma after anti–PD-1 therapy demonstrate on-treatment increase in abundance of 4-1BB+ CD4 T cells in blood
de Joode, K., Balcioglu, H. E., van Brakel, M., López-Cascales, M. T., Hurkmans, D. P., Basak, E. A., Hoop, E. O., Lamers, C. H. J., Aerts, J. G. J. V., Mathijssen, R. H. J., et al. (2026) · The Journal of Immunology · doi:10.1093/jimmun/vkag171
Advances in miRNA-Mediated Bidirectional Crosstalk and Immune Evasion Mechanisms Between Lung Cancer Cells and CD8+ T Cells
Zhou, X., Pang, T., & Ge, Z. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156918
TIM3 as a therapeutic target in anaplastic thyroid cancer: upregulation in M2 ‐like macrophages induced by tumor microenvironment‐derived TGFβ1
Jaroszewski, A., Choi, Y., Hellriegel, F., Zhang, W., Carrizo, F., Song, D. E., Laborié, M. V., Ruggieri, M., Peretti, E., Banus, M. V., et al. (2026) · The Journal of Pathology · doi:10.1002/path.70104
Spatial and functional specialization of human splenic innate lymphoid cells
Colpitts, S. J., Jegatheeswaran, S., Mashhouri, S., Hagerman, A., El-Maklizi, M., Murshed, H., Mak, M. L., Reid, K. T., Murphy, J. M., Mathews, J. A., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-76100-7
MSI-stratified analysis of TREM2 and HAVCR2 expression in mucinous colorectal adenocarcinoma: a structured analytical workflow with signature de-circularizationPreprint
Duan, Q. (2026) · Research Square · doi:10.21203/rs.3.rs-10441245/v1
Next-Generation Immune Checkpoint Inhibitors in Gastrointestinal Cancers: Mechanisms, Resistance, and Emerging Therapeutic Strategies
Ismail, M., Alabed, Z., Alhallaq, K., Al-Najjar, E., Mustafa, N., Aldroubi, Y., Hamdaneh, Y., & Esmail, A. (2026) · Cancers · doi:10.3390/cancers18162593
TIM3-targeted delivery of venetoclax overcomes drug resistance and reinvigorates NK cell activity in acute myeloid leukemia
Wang, Q., Li, J., Zeng, X., Liu, L., Lu, H., Zhao, Y., Huang, Y., Wang, R., Wang, C., Han, Y., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01217-z
From granulomas to tumors: post-tuberculosis immune and structural lung remodeling as a driver of carcinogenesis
Rukonge, P. A., Kawuribi, V., Lu, Z., Oluwaseun, A. F., Sheng, Y., Yan, K., Zheng, Z., Liu, X., Chu, L., & Yu, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1889276
Serum TIM-3 and Galectin-9 as Biomarkers and HAVCR2/LGALS9 Gene Polymorphisms in Iraqi Women with Breast Cancer
Alredha, R. D. A., Haddawi, K. H., & Hadi, S. H. (2026) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-026-02622-2
Zinc finger protein 600 is essential for the cytotoxic function of esophageal cancer-associated natural killer cells
He, J., Liu, S., Wang, L., & Xiong, F. (2026) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiag119
Targeting immunosuppressive tumor microenvironment to combat immunotherapy resistance: From mechanistic insights to therapeutic strategies
Su, P., Zhang, Y., Yu, T., 王元宇, 牟一平, & Jin, W. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117338
EXABS-120-MDS: Stalled Progress in Higher-Risk MDS: Can We Find an Off-Ramp?
Mina, A. A., & Zeidan, A. M. (2026) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/s2152-2650(26)00289-2
Targeting CARM1 impairs DNA damage repair and attenuates B-cell acute lymphoblastic leukemia progression
Liao, P., Qiu, Y., Li, M., Hu, R., Wang, H., Zhang, H., Wu, S., Liang, Z., & Li, Y. (2026) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2026.168444
microRNAs as Regulators of the Immune Response and Their Potential Therapeutic Applications in Cancer
Biltekin, E., & Özpolat, B. (2026) · Non-Coding RNA · doi:10.3390/ncrna12050034
A novel cyclic-peptide antagonist of TIM-3 for cancer immunotherapy by reinvigorating exhausted T-cell activity
Huang, Y., Li, J., Qin, Y., Qie, B., Wang, Q., Liu, C., & Zhu, Y. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179308
Immune Checkpoint Dysregulation in Epidermolysis Bullosa-Associated Squamous Cell Carcinomas Reveals an Immunosuppressive Tumor Microenvironment
Hassan, L., Khalaf, O., Jaber, R., & Mostafa, R. H. (2026) · Archive of International Journal of Cancer and Allied Science · doi:10.51847/rj1vtth4a1
Immune checkpoint knockout screen reveals TIGIT-CD155 interaction as a significant modulator of adapter CAR-T cell function in acute myeloid leukemia
Mast, A., Atar, D., Ruoff, L., Scheuermann, S., Kristmann, B., Lang, P., Seitz, C. M., & Schlegel, P. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2717853
PD-L1 in Merkel Cell Carcinoma: From Tumor Microenvironment to Pathological Interpretation
Pepe, L. R., Fiorentino, V., Mura, M. D., Rizzo, A., Santarpía, M., Ieni, A., Cazzato, G., & Lentini, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198460
Recent advances and future challenges of bispecific antibodies in lung cancer
Du, M., Han, Y., Jin, R., & Li, H. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105604
Natural killer cell-based therapy for hepatocellular carcinoma (HCC): A literature review
Widowati, W., Wargasetia, T. L., Sadri, B., Nainggolan, I. M., Azis, R., Rifana, S. D., Rismani, E., & Vosough, M. (2026) · Medical Oncology · doi:10.1007/s12032-026-03393-5
The Cardio-Onco-Immune Axis: immunopathological mechanisms in the cardiac microenvironment of checkpoint inhibitor-induced myocarditis
Liang, L.-K., Ye, Q., Li, J., Shi, L.-Y., Wang, S.-P., Liang, W.-J., Chen, A., & Feng, G. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01947-x
Tolerance–resistance continuum in immune checkpoint pathways: molecular architecture, spatial niches and clinical consequences
Sutanto, H., Fetarayani, D., Rachma, B., & Caesario, J. (2026) · BMJ Immunology · doi:10.1136/bmjimm-2025-000010
Lineage-specific immune checkpoint dynamics define a context-dependent regulatory framework with translational relevance in human γδ T cells
Corsale, A. M., Simone, M. D., Cerapio, J., Presti, E. L., Pizzolato, G., Avellone, C., Dieli, C., Marchiafava, S., Paola, L. D., Dieli, F., et al. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-09004-1
A pilot prospective cohort study: Changes in circulating T-lymphocyte subsets during steroid therapy in patients with nephrotic syndrome
Shan, Y., & Xie, Z. (2026) · Journal of International Medical Research · doi:10.1177/03000605261493753
Kinesin superfamily proteins in head and neck cancer: Mechanisms, clinical implications, and therapeutic potential
AlRamadneh, T. N., Renuka Jyothi, S., Nayak, P. P., Saheb, L., Ali, A. M., Arora, V., Chauhan, A. S., Garg, G., & Vahdati, S. N. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.104047
TIM ‐3 Functions as an Activator of NK Cells in GBM and Can Be Upregulated by Torin‐1: Implications for Exogenous NK Cell Transplantation
Liu, Y., Dao, T., Borde, S., Dinh, D., Lombardi, S., Torregrosa‐Allen, S. E., Harper, H. A., Slivova, V., Cohen‐Gadol, A., McIntosh, M., et al. (2026) · Immunology · doi:10.1111/imm.70211
Targeting the transcription factor SPI1 attenuates neuroinflammation and dopaminergic degeneration in Parkinson’s disease via the tim-3/NF-κb axis
Yin, X., Wang, M., Gao, Y., Yao, J., Li, Y., Chen, T., Wang, Z., Wang, W., & Gao, Z. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e01106
BindingDB Entry 50021559: Structure-Based Rational Design of Constrained Peptides as TIM-3 Inhibitors.
BindingDB (2025) · UC San Diego · doi:10.7270/q24m996w
BindingDB Entry 50020219: Discovery of Small-Molecule TIM-3 Inhibitors for Acute Myeloid Leukemia Using Pharmacophore-Based Virtual Screening.
BindingDB (2024) · UC San Diego · doi:10.7270/q2hx1j3x

Authors: Wolf, Y., Anderson, A. C., & Kuchroo, V. K.
Affiliations: Brigham and Women's Hospital (US)
Corresponding author: Kuchroo, Vijay K.
ORCID: Wolf, Yochai
Anderson, Ana C.
Kuchroo, Vijay K.
Venue: Nature Reviews Immunology
Publisher: Springer Science and Business Media LLC
Published: 2019-11-01
Volume: 20
Issue: 3
Pages: 173-185
ISSN: 1474-1733 (ISSN-L)
1474-1741
DOI: 10.1038/s41577-019-0224-6
PMC: PMC7327798
OpenAlex: W2985205513
Cited by: 959
References: 159
Citations by year: 2026: 98 · 2025: 140 · 2024: 191 · 2023: 160 · 2022: 183 · 2021: 142 · 2020: 44
FWCI: 8.75
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springernature.com/gp/researchers/text-and-data-mining (tdm)
www.springernature.com/gp/researchers/text-and-data-mining (vor)
Locations: Nature reviews. Immunology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health
National Cancer Institute (R01CA187975)
National Institute of Allergy and Infectious Diseases (P01AI073748, P01AI056299, P01AI039671)
National Institute of Neurological Disorders and Stroke (R01NS045937)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
Keywords: TIM-3, inhibitory receptors, co-inhibitory receptors, immune checkpoint, T cell exhaustion, loss-of-function mutations, antitumor immunity, chronic viral infection, cancer immunotherapy
MeSH terms: Hepatitis A Virus Cellular Receptor 2, Animals, Clinical Trials as Topic, Humans, Signal Transduction, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Programmed Cell Death 1 Receptor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

TIM3 comes of age as an inhibitory receptor

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks